JAK2-话题@MedSci

#JAK2#

19篇内容 | 1195人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217535, encodeId=2ba8221e5351c, content=<a href='/topic/show?id=ccf410109188' target=_blank style='color:#2F92EE;'>#食管癌#</a> <a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=b28f8901e30' target=_blank style='color:#2F92EE;'>#血小板减少症#</a> <a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=食管癌放疗联合免疫治疗后出现超进展，或与血小板减少症和JAK2拷贝数增加有关, objectType=article, longId=836880, objectId=3307836880a0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721282427434_92910.jpg, objectUrl=/article/show_article.do?id=3307836880a0, replyNumber=0, likeNumber=77, createdTime=2024-07-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3307836880a0, moduleTitle=食管癌放疗联合免疫治疗后出现超进展，或与血小板减少症和JAK2拷贝数增加有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3307836880a0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1488897, encodeId=6a10148889e1e, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Front Pharmacol:舒泻一号汤通过IL-6/JAK2/STAT3信号通路减轻慢性轻度不可预见性应激诱导的肝损伤, objectType=article, longId=728080, objectId=069ce2808010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=069ce2808010, replyNumber=0, likeNumber=62, createdTime=2022-05-30, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=069ce2808010, moduleTitle=Front Pharmacol:舒泻一号汤通过IL-6/JAK2/STAT3信号通路减轻慢性轻度不可预见性应激诱导的肝损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=069ce2808010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488896, encodeId=a7bf148889660, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。, objectType=article, longId=293934, objectId=e987293934a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e987293934a7, replyNumber=0, likeNumber=115, createdTime=2022-01-14, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e987293934a7, moduleTitle=AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e987293934a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488895, encodeId=a5781488895ed, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Leukemia： JAK2 和 ERK 的双重靶向干扰骨髓增殖性肿瘤克隆并提高治疗效果, objectType=article, longId=292080, objectId=dec9292080e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dec9292080e9, replyNumber=0, likeNumber=86, createdTime=2021-12-18, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dec9292080e9, moduleTitle=Leukemia： JAK2 和 ERK 的双重靶向干扰骨髓增殖性肿瘤克隆并提高治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dec9292080e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488894, encodeId=149f148889495, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Nat Commun : JAK2V617F 的克隆造血促进肺动脉高压，肺中性粒细胞中 ALK1 上调, objectType=article, longId=219430, objectId=d31021943025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31021943025, replyNumber=0, likeNumber=75, createdTime=2021-10-30, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31021943025, moduleTitle=Nat Commun : JAK2V617F 的克隆造血促进肺动脉高压，肺中性粒细胞中 ALK1 上调, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31021943025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488893, encodeId=016a148889351, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, objectType=article, longId=188485, objectId=ddfc1884854b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddfc1884854b, replyNumber=0, likeNumber=75, createdTime=2020-02-22, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddfc1884854b, moduleTitle=Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddfc1884854b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488892, encodeId=c78b14888922f, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关, objectType=article, longId=185564, objectId=35fa1855647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35fa1855647f, replyNumber=0, likeNumber=74, createdTime=2020-01-03, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35fa1855647f, moduleTitle=Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35fa1855647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488891, encodeId=50fa148889119, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：JAK2ex13Del驱动致癌转化，与慢性嗜酸性白血病和真性红细胞增多症相关, objectType=article, longId=181320, objectId=a75718132063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75718132063, replyNumber=0, likeNumber=90, createdTime=2019-10-17, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75718132063, moduleTitle=Blood：JAK2ex13Del驱动致癌转化，与慢性嗜酸性白血病和真性红细胞增多症相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a75718132063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488890, encodeId=84cf1488890ba, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点, objectType=article, longId=179590, objectId=f88b1e959038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88b1e959038, replyNumber=0, likeNumber=75, createdTime=2019-09-18, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88b1e959038, moduleTitle=Blood：JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88b1e959038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488889, encodeId=2f2714888896b, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, objectType=article, longId=177980, objectId=fe551e798093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe551e798093, replyNumber=0, likeNumber=99, createdTime=2019-08-21, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe551e798093, moduleTitle=FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe551e798093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488888, encodeId=ffc51488888fa, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点, objectType=article, longId=174843, objectId=33b11e4843cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33b11e4843cb, replyNumber=0, likeNumber=130, createdTime=2019-07-06, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33b11e4843cb, moduleTitle=Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33b11e4843cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488887, encodeId=d5ae148888eae, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：JAK2 V617F和CALR突变的人群发生率和表现, objectType=article, longId=170111, objectId=2f1f1e01113a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f1f1e01113a, replyNumber=0, likeNumber=120, createdTime=2019-06-26, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f1f1e01113a, moduleTitle=Blood：JAK2 V617F和CALR突变的人群发生率和表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f1f1e01113a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488886, encodeId=71af148888675, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, objectType=article, longId=161781, objectId=2f85161e81f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f85161e81f8, replyNumber=0, likeNumber=67, createdTime=2019-03-08, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f85161e81f8, moduleTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f85161e81f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488885, encodeId=3f1c1488885f3, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：Jak2V617F协同Dnmt3a缺失通过激活增强子驱动的炎症信号诱导骨髓纤维化, objectType=article, longId=151989, objectId=768d15198901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768d15198901, replyNumber=0, likeNumber=123, createdTime=2018-10-29, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768d15198901, moduleTitle=Blood：Jak2V617F协同Dnmt3a缺失通过激活增强子驱动的炎症信号诱导骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=768d15198901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488884, encodeId=e5ad148888424, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达, objectType=article, longId=150102, objectId=1ff11501029e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff11501029e, replyNumber=0, likeNumber=76, createdTime=2018-10-02, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff11501029e, moduleTitle=CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff11501029e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488883, encodeId=8b9b1488883e2, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Stem cells：JAK2V617F突变型巨核细胞可通过促血小板生成素/MPL信号促进造血干/祖细胞扩增, objectType=article, longId=145699, objectId=3bde145699a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bde145699a3, replyNumber=0, likeNumber=61, createdTime=2018-08-04, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bde145699a3, moduleTitle=Stem cells：JAK2V617F突变型巨核细胞可通过促血小板生成素/MPL信号促进造血干/祖细胞扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bde145699a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488882, encodeId=a1061488882ca, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=NEJM：扎心了！治疗骨髓纤维化的JAK2抑制剂竟会导致淋巴瘤！, objectType=article, longId=141213, objectId=82cd14121391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82cd14121391, replyNumber=0, likeNumber=129, createdTime=2018-06-22, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82cd14121391, moduleTitle=NEJM：扎心了！治疗骨髓纤维化的JAK2抑制剂竟会导致淋巴瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82cd14121391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488881, encodeId=59a714888812d, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=IGLH：JAK2或CALR突变的共存是骨髓增生性肿瘤临床上重要的事件？, objectType=article, longId=139536, objectId=a6da1395367c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6da1395367c, replyNumber=0, likeNumber=104, createdTime=2018-06-01, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6da1395367c, moduleTitle=IGLH：JAK2或CALR突变的共存是骨髓增生性肿瘤临床上重要的事件？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6da1395367c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488880, encodeId=126d148888095, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：JAK2抑制剂芦可替尼上市后的思考, objectType=article, longId=138017, objectId=3e8713801eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e8713801eaf, replyNumber=0, likeNumber=72, createdTime=2018-05-14, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e8713801eaf, moduleTitle=Blood：JAK2抑制剂芦可替尼上市后的思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e8713801eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488879, encodeId=598914888e97e, content=<a href='/topic/show?id=f9941022ee8' target=_blank style='color:#2F92EE;'>#JAK2#</a>, objectTitle=Blood：JAK2抑制剂用于治疗骨髓增生性肿瘤（MFN）的效果和安全性评估, objectType=article, longId=135312, objectId=411e1353128b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=411e1353128b, replyNumber=0, likeNumber=114, createdTime=2018-04-15, rootId=0, userName=gao_jian4220, userId=666c8479565, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=411e1353128b, moduleTitle=Blood：JAK2抑制剂用于治疗骨髓增生性肿瘤（MFN）的效果和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=411e1353128b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JAK2

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#食管癌# #免疫治疗# #血小板减少症# #JAK2#

食管癌放疗联合免疫治疗后出现超进展，或与血小板减少症和JAK2拷贝数增加有关

2024-07-30发表于上海

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Front Pharmacol:舒泻一号汤通过IL-6/JAK2/STAT3信号通路减轻慢性轻度不可预见性应激诱导的肝损伤

2022-05-30

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。

2022-01-14

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Leukemia： JAK2 和 ERK 的双重靶向干扰骨髓增殖性肿瘤克隆并提高治疗效果

2021-12-18

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Nat Commun : JAK2V617F 的克隆造血促进肺动脉高压，肺中性粒细胞中 ALK1 上调

2021-10-30

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

2020-02-22

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关

2020-01-03

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：JAK2ex13Del驱动致癌转化，与慢性嗜酸性白血病和真性红细胞增多症相关

2019-10-17

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点

2019-09-18

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

FDA批准Celgene的JAK2抑制剂Inrebic治疗骨髓纤维化

2019-08-21

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：SLAMF7high 单核细胞增多可作为埃罗妥珠单抗治疗JAK2V617F(+)骨髓纤维化患者的治疗靶点

2019-07-06

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：JAK2 V617F和CALR突变的人群发生率和表现

2019-06-26

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化

2019-03-08

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：Jak2V617F协同Dnmt3a缺失通过激活增强子驱动的炎症信号诱导骨髓纤维化

2018-10-29

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达

2018-10-02

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Stem cells：JAK2V617F突变型巨核细胞可通过促血小板生成素/MPL信号促进造血干/祖细胞扩增

2018-08-04

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

NEJM：扎心了！治疗骨髓纤维化的JAK2抑制剂竟会导致淋巴瘤！

2018-06-22

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

IGLH：JAK2或CALR突变的共存是骨髓增生性肿瘤临床上重要的事件？

2018-06-01

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：JAK2抑制剂芦可替尼上市后的思考

2018-05-14

gao_jian4220 (审核中...)

前往app查看评论内容

#JAK2#

Blood：JAK2抑制剂用于治疗骨髓增生性肿瘤（MFN）的效果和安全性评估

2018-04-15

科室
- - 订阅+
  - 更多科室
工具
服务